Targeting Breast Cancer Using Hyaluronic Acid-Conjugated Liposomes Triggered with Ultrasound

The successful targeting of tumors can be achieved by conjugating moieties to nanoparticles. These modifications allow nannocarriers achieve greater specificity through binding specific receptors overexpressed on the surface tumor cells. In this study, pegylated liposomes encapsulating model drug/dye calcein and conjugated hyaluronic acid (HA) molecules were successfully synthesized, their ability target HA a breast cancer cell line was investigated in vitro . Low-frequency ultrasound (LFUS), applied at three different power densities (6.2, 9, 10 mW/cm 2 ) used trigger release entrapped calcein. Both control HAconjugated showed similar profiles. conjugation resulted significant increase uptake MDA-MB-231 known for its CD44 (HA receptor) overexpression, while such an effect not recorded with NIH-3T3, embryonic mouse fibroblast, low levels expression. application LFUS enhancement cells from our liposome compared without exposure ultrasound. findings suggest that combining HA-conjugated is promising drug delivery platform treatment.